Top Markets
#1 AntFun AntFun +58.69%
#2 BankrCoin BankrCoin +22.98%
#3 EXOD EXOD +21.04%
#4 ZetaChain ZetaChain +16.29%
#5 Fake World Assets Fake World Assets +14.27%
#6 Venom Venom +12.87%
#7 CARV CARV +10.82%
#8 StonkBroker StonkBroker +10.81%
#9 Black Phoenix Black Phoenix +10.04%
#10 Phala Phala +9.50%
Coin of the day
AntFun AntFun
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Kedudukan dalam Saham #107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Harga Saham
$41.14
Disegerakkan terakhir: 2026-09-21
Modal Pasaran
$182.76B
Perubahan (1 hari)
-7.78%
Perubahan (1 tahun)
-32.24%
Negara
DK
Perdagangan Novo Nordisk A/S (NOVO-B)

Kategori

Healthcare
Nisbah P/E bagi Novo Nordisk A/S (NOVO-B)
Nisbah P/E pada September 2026 TTM: 10.69
Menurut laporan kewangan dan harga saham terkini Novo Nordisk A/S, nisbah P/E semasa (TTM) ialah 10.69. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 27.53.
Sejarah nisbah P/E bagi Novo Nordisk A/S dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 10.69 -24.21%
2025 14.11 -48.75%
2024 27.53 -26.39%
2023 37.40 -2.28%
2022 38.27 8.25%
2021 35.35 49.61%
2020 23.63 0.26%
2019 23.57 23.65%
2018 19.06 -12.01%
2017 21.66 27.49%
2016 16.99 -42.39%
2015 29.49 14.43%
2014 25.77 21.85%
2013 21.15 -11.44%
2012 23.88 9.42%
2011 21.83 -13.90%
2010 25.35 37.23%
2009 18.48 6.65%
2008 17.32 -27.90%
2007 24.03 1.28%
2006 23.72 19.31%
2005 19.88 -0.71%
2004 20.02 18.71%
2003 16.87 -2.64%
2002 17.33 -43.27%
2001 30.54 -2.36%
2000 31.28 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 38.12 256.42%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 30.79 187.90%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 73.73 589.43%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 22.25 108.04%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 114.95 974.91%
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.